AB Science SA to Receive EUR 5.9 Million Subsidy as Leader of Consortium Created for Development of New Alzheimer's Disease Therapy

Tuesday, 23 Jul 2013 02:46am EDT 

AB Science SA announced the creation of a partnership in the development of a new targeted therapy in Alzheimer's disease. The consortium will receive EUR 8.6 million from Bpifrance, the French state innovation agency, within the framework of the Industrial Strategic Innovation (ISI) program, and gathers together ABScience, the Brain and Spine Institute (ICM), MIRCen from the Atomic Energy Commission (CEA), the National Institute of Health and Medical Research (INSERM), Imagine Foundation and Skuldtech, a biotechnology company specialized in the discovery of biomarkers and development of diagnostic and testing tools companions. AB Science SA, initiator and leader of this project entitled ROMANE (Role of Mast Cells in Neurology), will receive a total amount of EUR 5.9 million from Bpifrance in the form of grants and repayable advances.